We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Zolgensma Novartis Pharmaceuticals Australia Pty Ltd
Product name
Zolgensma
Accepted date
Nov-2024
Active ingredients
onasemnogene abeparvovec
Proposed indication
Zolgensma is a gene therapy for children who have spinal muscular atrophy (SMA) with alterations in the SMN1 gene.
Application type
C (new indication)
Publication date
Nov-2024